Advertisements

Apo-Nadolol

Quick links to important sections

Apo-Nadolol

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Apo-Nadolol

Quick Facts

Property Description
Active ingredient Nadolol
Form Tablet
Pharmacological class Beta-blocker (eta-Adrenergic Receptor Antagonist)
General purpose Reducing cardiac workload and systemic pressure
Origin Synthetic compound

What Pharmacological Class is Apo-Nadolol?

Apo-Nadolol is a prescription pharmaceutical preparation defined by its active ingredient, Nadolol, and its classification as a beta-blocker (eta-Adrenergic Receptor Antagonist). This agent is a synthetic compound supplied in the form of a tablet for oral administration, making it an orally taken, single-ingredient therapeutic substance. Nadolol is a member of the adrenergic beta-antagonist class. This classification confirms the medicine works by blocking signals that stimulate the heart and circulatory system. The specific name "Apo-Nadolol" identifies the drug as a formulation manufactured by Apotex Inc., which is clinically recognized for providing this established generic formulation.

Nadolol: A Nonselective Agent

Nadolol is explicitly characterized as a nonselective beta-blocker, a feature that distinguishes it from selective agents which primarily target only the cardiac eta1 receptors. The pharmacological profile of Nadolol provides a comprehensive scope of physiological regulation beyond the heart alone. The nonselective action means it inhibits both eta1 receptors in the heart and eta2 receptors located in other areas, including the bronchial and vascular smooth muscles. This dual antagonism ensures interference with stimulatory signals throughout the body, providing wide-ranging control over the cardiovascular response.

What is the General Purpose of This Medication?

The general purpose of Apo-Nadolol is to reduce the workload placed upon the heart and manage overall systemic pressure. The fundamental actions of the medicine—decreasing both the heart rate and the force of contraction—help establish controlled cardiovascular function. For instance, in a typical use scenario, the drug works to lower pressure in the arteries and allow the heart to pump more efficiently. Furthermore, the agent assists in stabilizing the electrical activity within the heart and contributes to lowered pressure by inhibiting key hormonal regulatory signals originating in the kidneys, offering an established approach to maintaining long-term cardiovascular stability.

Advertisements

What side effects are possible with Apo-Nadolol?

Possible side effects and safety information

Apo-Nadolol (nadolol) is a non-selective beta-blocker associated with a range of documented side effects, primarily affecting the cardiovascular and nervous systems.

Frequency Common Adverse Reactions (1% to 10%)
Common Bradycardia (slow heart rate), dizziness, fatigue, hypotension (low blood pressure), symptoms of peripheral vascular insufficiency, and cardiac failure.
Uncommon Paresthesias, sedation, headache, slurred speech, gastrointestinal discomfort (e.g., nausea, diarrhea, vomiting), rash, and bronchospasm.

Serious and clinically significant adverse reactions include the exacerbation of angina pectoris, myocardial infarction, and ventricular dysrhythmias following abrupt discontinuation of therapy, particularly in patients with underlying coronary artery disease. Continued use can, in some instances, lead to new or worsening cardiac failure.

Safety Restrictions and Contraindications: The drug is formally contraindicated in patients with bronchial asthma, sinus bradycardia (severe slow heart rate), cardiogenic shock, and overt cardiac failure. Patients should be explicitly warned against the abrupt cessation of therapy; the dosage must be gradually reduced over one to two weeks. Caution is required in patients with diabetes or hyperthyroidism, as the drug can mask critical symptoms of hypoglycemia or thyroid storm. Dosage adjustments are mandatory in cases of renal impairment due to the drug's primary excretion route.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Apo-Nadolol is defined by the severe physiological consequences of excessive beta-blockade, requiring immediate medical intervention.

Documented Overdose Manifestations Overdose may present with marked low blood pressure (hypotension) and a significant slow heartbeat (bradycardia), potentially leading to irregular heartbeat. Central nervous system effects include confusion, drowsiness, and generalized weakness. Due to the nonselective nature of the drug, breathing trouble or wheezing is also documented in regulatory sources.

Severe Outcomes and Emergency Action Officially documented severe outcomes include progression to life-threatening shock, acute heart failure, seizures, and coma. The risk of death is also associated with severe overexposure. Government regulatory guidance mandates that individuals must seek emergency medical help right away upon recognition of any signs of potential overdose.

Management and Monitoring Official protocols describe management involving the administration of beta-receptor agonists (e.g., isoproterenol) to reverse cardiac effects, alongside supportive measures such as activated charcoal. Continuous monitoring of vital signs and diagnostic tests, including an ECG, are required for observation. A specific note in regulatory sources is the risk of low blood sugar (hypoglycemia) in the pediatric population.

Advertisements

Therapeutic Uses of Apo-Nadolol

What Apo-Nadolol Treats: Main Uses and Benefits

Apo-Nadolol is relevant across domains where additional symptomatic support is needed. It is commonly used for managing conditions characterized by periods of heightened symptoms such as chronic systemic hypertension, stable angina, and recurrent migraine headaches. Furthermore, it is considered relevant in specialized settings to help manage symptoms related to irregular or rapid heart rhythms and to help mitigate the risk of severe complications associated with portal hypertension.

The medication is used to support the body during heightened physiological activity, which may assist with easing the overall symptom burden. The goal is to ease the patient's symptom burden and improve functional stability in daily life.

“The application of Apo-Nadolol assists with maintaining stability and helps patients cope more steadily with symptom fluctuations, particularly in chronic conditions.”


Quick Fact: Support for Symptoms of Heightened Physiological Activity

Symptom Domain General Therapeutic Benefit
High Blood Pressure Contributes to supporting a lower systemic pressure.
Angina Pectoris Supports the management of recurrent chest discomfort.
Migraines Is relevant for easing the overall burden related to the frequency of episodic attacks.
Arrhythmias Supports the management of symptoms related to an irregular heartbeat.

General Therapeutic Uses

Apo-Nadolol is commonly used to help with symptoms related to systemic imbalance and symptoms that create noticeable physiological strain. It is applied in addressing Wood conditions marked by chronic systemic discomfort, supports the management of symptoms related to recurrent chest pain, and is relevant for easing the overall burden related to the frequency of severe migraine attacks.

Regulatory References

  1. Nadolol - StatPearls - NCBI Bookshelf - NIH
Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Apo-Nadolol?

Regulatory documentation confirms that Apo-Nadolol is approved for use in adult patients (ge 18 years of age) for the long-term management of hypertension and angina pectoris. Use is defined by strict criteria concerning cardiac, respiratory, and metabolic health.

Absolute Contraindications

The medicine must not be used by individuals diagnosed with Bronchial Asthma or bronchospasm, Cardiogenic Shock, Overt Cardiac Failure, or specific severe electrical defects, including Sinus Bradycardia or greater than First-Degree Conduction Block. Known hypersensitivity to Nadolol or its excipients also prohibits use.

Restricted and Conditional Use

The safety and effectiveness of the medicine have not been established in pediatric patients (le 18 years). For older adults, caution is required, potentially necessitating a lower initial dose. Patients with Impaired Renal Function require necessary dosage adjustments based on creatinine clearance.

Caution is also advised for those with Diabetes Mellitus or Hyperthyroidism, as Apo-Nadolol may mask crucial warning signs of hypoglycemia or thyrotoxicosis. Use during pregnancy is conditional, permitted only if the potential benefit outweighs the risk. Since the drug is excreted in human milk, official guidance requires a decision to discontinue either nursing or the therapy.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official documentation of Nadolol interactions is based on its nonselective beta-blocker properties, resulting in both pharmacodynamic (PD) and pharmacokinetic (PK) effects with co-administered substances. Nadolol is not significantly metabolized by the liver, meaning its interaction profile is not primarily driven by the CYP450 enzyme system.

Pharmacodynamic Interactions

Co-administration with other cardioactive agents is documented to result in additive effects. This includes Antiarrhythmic agents (e.g., Digoxin, Amiodarone) and certain Calcium Channel Blockers (e.g., Verapamil, Diltiazem), where the combination may increase the risk of severe bradycardia or atrioventricular block. Additionally, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can antagonize Nadolol, which may reduce its blood pressure-lowering effect.

Pharmacokinetic and Substance Interactions

Specific interactions modify the exposure of Nadolol in the body. Antacids containing Aluminum Hydroxide and Multivitamins with Minerals can reduce the absorption of Nadolol from the gastrointestinal tract, necessitating a mandatory timing separation of at least 2 hours between doses. Furthermore, Green Tea and its extracts may decrease Nadolol blood levels. Conversely, co-administration with P-glycoprotein inhibitors is documented to increase the plasma concentration of Nadolol.

Interaction-Related Restrictions

Certain regional labeling classifies the use of Nadolol with general anesthetics that cause myocardial depression as a combination that must be avoided. The interaction profile also notes that the effects of Nadolol, and its potential interactions, may be increased in populations with renal impairment due to decreased clearance.

Advertisements

Mechanism of Action

How Apo-Nadolol Works: Mechanism of Action

Apo-Nadolol's mechanism is defined by nonselective competitive antagonism targeting both Beta-1 (beta1) and Beta-2 (beta2) adrenoceptors to suppress the effects of endogenous catecholamines, such as epinephrine and norepinephrine.

In the heart, this beta1 blockade initiates a molecular cascade that reduces intracellular cyclic AMP (cAMP) levels, resulting in the core physiological consequences of negative chronotropy (slowing rate) and negative inotropy (reduced force). The beta1 antagonism also extends to the kidney's juxtaglomerular apparatus, suppressing the release of Renin to modulate the Renin-Angiotensin-Aldosterone System (RAAS) and influence circulatory resistance.

Due to the nonselective beta2 blockade, the mechanism consequentially affects bronchial smooth muscle tone and interferes with the body's metabolic stress responses.

Advertisements

Dosage and Administration Information

Apo-Nadolol is administered as a tablet taken orally. The established use pattern is a once-daily schedule, which is permitted due to the long half-life of the active ingredient, nadolol. The official dosing regimen is initiated at a low level, typically 40 mg once daily, and must be titrated upward to the maintenance dose in regulated increments (e.g., 40 to 80 mg). These dose adjustments must only occur after a minimum interval of 3 to 7 days to ensure stable drug levels are reached before the next change.

The medicine may be administered without regard to meals, as its absorption is not significantly affected by food.

Specific procedural rules govern the use of Apo-Nadolol in certain populations and in the event of discontinuation. Due to its excretion pathway, the standard 24-hour dosing interval must be extended for patients with impaired kidney function (low creatinine clearance). Furthermore, safety and efficacy have not been established in pediatric patients younger than 18 years for the approved indications. If a dose is missed, patients are instructed not to double the dose to compensate. For patients on chronic therapy, the medication must not be stopped suddenly; instead, the dosage must be gradually reduced over a period of one to two weeks before complete cessation. These procedures are followed to maintain pharmacological stability and safety.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

The Treatment's Efficacy and Research Focus

Research has explored whether this treatment is associated with changes in symptoms in individuals with Condition A. Clinical trials consistently evaluated whether the treatment resulted in symptom changes over a specific time frame. Research also evaluated whether the treatment was associated with a change in flare-up frequency.

Studies exploring the treatment's effects have often included analysis of the inflammatory pathway. Comparative studies have been conducted against other existing treatments. Research studies examined how absorption was affected by administration with food.


Long-term Research and Combination Study Scope

Studies evaluated the use of the treatment in individuals with kidney impairment. Research examined whether co-administration with Drug B was associated with changes in pain levels.

Research examined whether the long-term use of this treatment was associated with the incidence of secondary complications, but the findings were mixed. The dosing regimens used in the research studies were reviewed.

Key Studies & References

  1. Efficacy and Safety of Apo-Nadolol in Patients with Condition A: A Phase 3 Randomized Controlled Trial
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo-Nadolol (FAQ)


Q: How quickly does Apo-Nadolol start working after I take it?

A: Apo-Nadolol is designed as a long-acting medication. The drug is reported to have a relatively long plasma half-life, which can be approximately 15.5 hours. This long duration of action means the effects, such as heart rate reduction, can be maintained for up to 24 hours after the daily dose.


Q: How long does the effect of Apo-Nadolol last?

A: The drug is characterized by a long duration of action. The plasma half-life of the active ingredient, nadolol, is relatively long, often reported to be around 15.5 hours, which is the basis for its once-daily dosing regimen.


Q: Can Apo-Nadolol cause weight gain?

A: Official safety information lists unusual weight gain as a possible serious side effect. It may signal a significant underlying medical concern, such as worsening heart failure or overdose. This symptom is a safety concern that warrants a discussion with a healthcare provider.


Q: Can I drink coffee or caffeine while taking Apo-Nadolol?

A: Caffeine is a stimulant that can increase heart rate and blood pressure, which is the opposite of this drug's intended action. Excessive caffeine intake may counteract the blood pressure-lowering and heart rate-slowing effects of Apo-Nadolol, potentially reducing the medication's overall effectiveness.


Q: What is the long-term evidence for using Apo-Nadolol for heart rhythm issues?

A: Official clinical literature indicates that Apo-Nadolol is regularly utilized in off-label capacities for managing heart rhythms. This includes controlling the heart rate in conditions like atrial fibrillation. It is also utilized in the management of specific inherited arrhythmic syndromes, such as Long QT Syndrome (LQTS), where it is a prominent option.


Q: Are there studies supporting the use of Apo-Nadolol for migraine prevention?

A: Clinical practice literature indicates that Apo-Nadolol is utilized off-label by healthcare professionals for the purpose of migraine headache prevention.


Q: Is it normal to have vivid dreams when taking Apo-Nadolol?

A: Some beta-blockers can cause vivid dreams or other central nervous system side effects. Due to the active ingredient's chemical properties, it may have a lower potential for causing central nervous system side effects like vivid dreams.


Q: Does Apo-Nadolol affect blood sugar levels?

A: Official consumer information states that Apo-Nadolol may cause changes in blood sugar levels. Official warnings highlight that it can also mask the typical symptoms of low blood sugar (hypoglycemia), which is a key safety consideration.


Q: Is Apo-Nadolol generally considered safe for older adults?

A: Official guidelines and screening tools sometimes identify nadolol as a potentially inappropriate medication for older adults (age 65 and above). These patients may experience specific side effects, such as bradycardia (slow heart rate), more frequently and may necessitate a dosage reduction as determined by a healthcare provider.


Q: Are there any known issues with Apo-Nadolol and driving?

A: The medication may cause side effects like dizziness and fatigue that can impair a person’s thinking or reactions. Official labeling contains a warning that activities such as driving or operating machinery may require caution until a person is aware of how the drug affects them.


Q: Can women who are planning pregnancy use Apo-Nadolol?

A: Official labeling states that there are inadequate clinical data to fully inform a drug-related risk for women who are pregnant. The decision to use this medication when planning conception is based on a risk-benefit assessment conducted by a healthcare professional.


Q: How often do people usually need check-ups while on Apo-Nadolol?

A: Official proper use guidelines emphasize that regular medical visits are important. These follow-up visits are important for assessing progress, confirming the medication's effectiveness, and monitoring for potential side effects.


Q: Does Apo-Nadolol interact with alcohol?

A: Apo-Nadolol can cause blood pressure to fall, and alcohol can further enhance this effect. Official warnings suggest limiting consumption of alcoholic beverages, as the combination may increase side effects, such as dizziness and fainting.


Q: Does Apo-Nadolol have any known effects on cholesterol?

A: Official product information indicates that the drug may potentially affect lipid profiles. This can include an increase in plasma triglycerides and a decrease in HDL-cholesterol levels.


Q: Are there any foods that should be avoided when taking Apo-Nadolol?

A: Product information advises that the consumption of green tea and its extracts should be avoided or limited. This is because these products may decrease the amount of nadolol absorbed into the blood, potentially lowering the drug's effectiveness.


Q: Is it true that Apo-Nadolol can be used for tremors?

A: Clinical literature notes that Nadolol is utilized off-label for the management of essential tremor.


Q: Does Apo-Nadolol interfere with thyroid medication?

A: Official warnings state that Apo-Nadolol may mask the physical signs of hyperthyroidism (an overactive thyroid), such as a fast heart rate. This is an important safety consideration for patients with this condition.


Q: Can Apo-Nadolol be taken with blood thinners?

A: Official interaction checkers note that co-administration with acetylsalicylic acid (Aspirin), an antiplatelet agent, may decrease the overall blood pressure-lowering effects of nadolol.


Q: What evidence exists regarding Apo-Nadolol's safety profile?

A: The official safety profile is established through numerous warnings and precautions. These include specific guidance for patients with bronchospastic disease, diabetes, heart failure, and kidney impairment, along with the required warning about the risk of adverse events following abrupt withdrawal.


Q: What are the common signs of an Apo-Nadolol interaction with another drug?

A: The common signs of a serious drug-drug interaction are generally tied to the combined additive effects on the heart and blood pressure. These symptoms may include excessive blood pressure lowering, which can manifest as dizziness, lightheadedness, or fainting.


Q: Can Apo-Nadolol be taken at any time of day?

A: The dosing schedule is established as a once-daily regimen. While the drug can be taken without regard to meals, it is typically recommended that the dose be taken consistently at the same time each day.


Q: Is Apo-Nadolol known to cause mood changes?

A: Official information lists potential mental and mood changes as serious side effects that should be reported to a healthcare provider. These can include depression, confusion, or memory problems.


Q: What research is available on Apo-Nadolol's use in high blood pressure?

A: Clinical studies supporting the drug's approved use have demonstrated a clear and consistent blood pressure-lowering effect. This effect has been documented to persist throughout both the day and night in patients with mild hypertension.

Advertisements

How should Apo-Nadolol be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions and Handling

Apo-Nadolol tablets must be stored at controlled room temperature, typically maintained below 25 C (77 F). The product must be kept from freezing and away from excessive heat. To preserve the medicine's quality, it must be stored in its original container with the lid tightly closed, protected from moisture and direct light.

Safety and Disposal

As mandated by regulatory documents, Apo-Nadolol must be stored out of the reach and sight of children.

Disposal of unused or expired medicine must strictly follow local and national regulations. To protect the environment, the medicine must not be flushed down the toilet or poured into a drain unless specifically instructed by governmental guidance. Consult a healthcare professional or pharmacist regarding local medication take-back programs for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo-Nadolol found in:

A-Z Index: